"Antidepressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.
| Descriptor ID |
D000928
|
| MeSH Number(s) |
D27.505.954.427.700.122
|
| Concept/Terms |
Antidepressive Agents- Antidepressive Agents
- Agents, Antidepressive
- Antidepressant Drugs
- Drugs, Antidepressant
- Antidepressants
|
Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents".
This graph shows the total number of publications written about "Antidepressive Agents" by people in this website by year, and whether "Antidepressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 3 | 4 |
| 2000 | 3 | 2 | 5 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 5 | 1 | 6 |
| 2004 | 4 | 1 | 5 |
| 2005 | 3 | 8 | 11 |
| 2006 | 7 | 5 | 12 |
| 2007 | 6 | 4 | 10 |
| 2008 | 7 | 5 | 12 |
| 2009 | 6 | 5 | 11 |
| 2010 | 6 | 5 | 11 |
| 2011 | 9 | 4 | 13 |
| 2012 | 6 | 5 | 11 |
| 2013 | 5 | 7 | 12 |
| 2014 | 5 | 3 | 8 |
| 2015 | 9 | 4 | 13 |
| 2016 | 6 | 2 | 8 |
| 2017 | 10 | 4 | 14 |
| 2018 | 6 | 6 | 12 |
| 2019 | 8 | 5 | 13 |
| 2020 | 8 | 15 | 23 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 15 | 15 |
| 2023 | 3 | 8 | 11 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antidepressive Agents" by people in Profiles.
-
Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin. Am J Ther. 2024 Mar-Apr 01; 31(2):e121-e132.
-
Psychedelic Therapy: A Primer for Primary Care Clinicians-3,4-Methylenedioxy-methamphetamine (MDMA). Am J Ther. 2024 Mar-Apr 01; 31(2):e141-e154.
-
Neural connectivity moderators and mechanisms of ketamine treatment among treatment-resistant depressed patients: a?randomized controlled trial. EBioMedicine. 2024 Jan; 99:104902.
-
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Neuropsychopharmacology. 2024 Jan; 49(2):467-475.
-
Exploring the prevalence of antidepressant medication discontinuation among pregnant veterans. Arch Womens Ment Health. 2024 Feb; 27(1):89-97.
-
Poststroke Depression: An Update. J Neuropsychiatry Clin Neurosci. 2024; 36(1):22-35.
-
The why, when, where, how, and so what of so-called rapidly acting antidepressants. Neuropsychopharmacology. 2024 Jan; 49(1):189-196.
-
Reduction in Cognitive Symptoms Following Intranasal Esketamine Administration in Patients With Chronic Treatment-resistant Depression: A 12-Week Case Series. J Psychiatr Pract. 2023 07 01; 29(4):325-332.
-
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023 Jun 22; 388(25):2315-2325.
-
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593.